Simultaneous determination of methylenetetrahydrofolate reductase C677T and factor V G1691A genotypes by mutagenically separated PCR and multiple- injection capillary electrophoresis

Clinical Chemistry

Volumn 44, Issue 2, 1998, Pages 264-269

  Ulvik, Arve ^a   Ren, Jicun ^a   Refsum, Helga ^a   Ueland, Per Magne ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5;

ALLELE; ARTICLE; ASSAY; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; FLUORESCENCE; GENE; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RISK FACTOR; THROMBOEMBOLISM;

EID: 0031887594     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.2.264     Document Type: Article

References (28)

1. Rees DC, Cox M, Clegg JB. Detection of the factor V Leiden mutation using whole blood PCR. Thromb Haemost 1996;75: 520-1.
2. Dahlbäck B. Inherited thrombophilia to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995;85: 607-14.
3. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden. Blood 1995;85:1504-8.
4. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817-21.
5. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. Identification of a candidate genetic risk factor for vascular disease: a common mutation at the methylenetetrahydrofolate reductase locus. Nature Genet 1995;10:111-3.
6. Rozen R. Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Clin Invest Med 1996;19:171-8.
7. Guttormsen AB, Ueland PM, Nesthus I, Nygård O, Schneede J, Vollset SE, Refsum H. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 μmol/liter). The Hordaland homocysteine study. J Clin Invest 1996;98:2174-83.
8. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62.
9. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R, et al. Homocysteine and risk of premature coronary heart disease: evidence for a common gene mutation. Circulation 1996;94:2154-8.
10. Izumi M, Iwai N, Ohmichi N, Nakamura Y, Shimoike H, Kinoshita M. Molecular variant of 5,10-methylenetetrahydrofolate reductase risk factor of ischemic heart disease in the Japanese population. Atherosclerosis 1996;121:293-4.
11. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, van Oost BA, den Heijer M, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35-41.
12. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997;95:2032-6.
13. Kluijtmans LAJ, Kastelein JJP, Lindemans J, Boers GHJ, Heil SG, Bruschke AVG, et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1997;96:2573-7.
14. Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs C, et al. Coexistence of hereditary homocystinuria and factor V Leiden: effect on thrombosis. N Engl J Med 1996;334:763-8.
15. Peng FY, Triplett D, Barna L, Morrical D. Pulmonary embolism and premature labor in a patient with both factor V Leiden mutation and methylenetetrahydrofolate reductase gene C677T mutation. Thromb Res 1996;83:243-51.
16. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow RM, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777-82.
17. Bertina RM, Koelman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
18. Greengard JS, Xu X, Gandrille S, Griffin JH. Alternative PCR method for diagnosis of mutation causing activated protein C resistant Gln-506-factor V. Thromb Res 1995;80:441-3.
19. Kirschbaum NE, Foster PA. The polymerase chain reaction with sequence specific primers for the detection of factor V mutation associated with activated protein C resistance. Thromb Haemost 1995;74:874-8.
20. Bellissimo DB, Kirschbaum NE, Foster PA. Improved method for factor V Leiden typing by PCR-SSP. Thromb Haemost 1996;75: 520.
21. Benson JM, Phillips DJ, Holloway BP, Evatt BL, Hooper WC. Oligonucleotide ligation assay for detection of the factor V mutation (Arg506-Gln) causing protein C resistance. Thromb Res 1996;83:87-96.
22. Rust S, Funke H, Assmann G. Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. Nucleic Acids Res 1993;21:3623-9.
23. St. Claire RL. Capillary electrophoresis. Anal Chem 1996;68: R569-86.
24. Ulvik A, Refsum H, Kluijtmans LAJ, Ueland PM. C677T mutation of the methylenetetrahydrofolate reductase gene determined in human blood or plasma by multiple-injection capillary electrophoresis and laser-induced fluorescence detection. Clin Chem 1997; 43:267-72.
25. Hjertén S. High-performance electrophoresis. Elimination of electroendosmosis and solute adsorption. J Chromatogr 1985;347: 191-8.
26. Goodman MF. DNA polymerase fidelity: misinsertions and mismatched extensions. In: Innis MA, ed. PCR strategies. San Diego: Academic Press, 1995:17-31.
27. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989;17:2503-16.
28. Zoller B, Holm J, Svensson P, Dahlbäck B. Elevated levels of prothrombin activation fragment 1 and 2 in plasma from patients with heterozygous Arg-506 to GIn mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost 1996;75:270-4.